Mark A. Weiss

7.0k total citations · 3 hit papers
148 papers, 5.1k citations indexed

About

Mark A. Weiss is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Mark A. Weiss has authored 148 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Genetics, 32 papers in Pulmonary and Respiratory Medicine and 32 papers in Hematology. Recurrent topics in Mark A. Weiss's work include Chronic Lymphocytic Leukemia Research (35 papers), Lymphoma Diagnosis and Treatment (26 papers) and Acute Lymphoblastic Leukemia research (17 papers). Mark A. Weiss is often cited by papers focused on Chronic Lymphocytic Leukemia Research (35 papers), Lymphoma Diagnosis and Treatment (26 papers) and Acute Lymphoblastic Leukemia research (17 papers). Mark A. Weiss collaborates with scholars based in United States, Germany and Canada. Mark A. Weiss's co-authors include Inge Bernstein, Stuart M. Brooks, Raymond P. Warrell, Stanley R. Frankel, A Eardley, Gregory Y. Lauwers, Victor E. Pollak, John D. Crissman, M. Roy First and Renier J. Brentjens and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Mark A. Weiss

143 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

1992 513 citations Stanley R. Frankel, A Eardley et al. Annals of Internal Medicine profile →
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

2003 513 citations Mark A. Weiss et al. profile →
Reactive Airways Dysfunction Syndrome (RADS)

1985 470 citations Mark A. Weiss et al. profile →

Peers

Countries citing papers authored by Mark A. Weiss

Since Specialization

Citations

This map shows the geographic impact of Mark A. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Weiss more than expected).

Fields of papers citing papers by Mark A. Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Weiss. The network helps show where Mark A. Weiss may publish in the future.

Co-authorship network of co-authors of Mark A. Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Weiss. A scholar is included among the top collaborators of Mark A. Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Weiss. Mark A. Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Did border closures slow SARS-CoV-2? 2022 ·Scientific Reports ·(unknown), (unknown), (unknown), Mark A. Weiss, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	27
2	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition 2018 ·Investigational New Drugs ·Margaret Kasner, Rosemarie Mick, Grace R. Jeschke, Matthew Carabasi, Joanne Filicko-O’Hara, Neal Flomenberg, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, James K. Mangan, John L. Wagner, Mark A. Weiss, Martin Carroll, Alexander E. Perl	17
3	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States 2017 ·BMC Cancer ·Chadi Nabhan, Anthony R. Mato, Christopher R. Flowers, David L. Grinblatt, Nicole Lamanna, Mark A. Weiss, Matthew S. Davids, Arlene S. Swern, (unknown), Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Jeff P. Sharman	8
4	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation 2015 ·Biology of Blood and Marrow Transplantation ·Sameh Gaballa, Neil Palmisiano, Önder Alpdoğan, Matthew Carabasi, Joanne Filicko-O’Hara, Margaret Kasner, Walter K. Kraft, Benjamin E. Leiby, Ubaldo Martinez‐Outschoorn, (unknown), Barbara Pro, (unknown), Manish Sharma, John L. Wagner, Mark A. Weiss, Neal Flomenberg, Dolores Grosso	21
5	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia 2013 ·Supportive Care in Cancer ·Chris L. Pashos, Christopher R. Flowers, Neil E. Kay, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Susan Lerner, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, M. Kozloff, Arlene S. Swern, (unknown), Kristen Sullivan, Gale Harding, Zeba M. Khan	29
6	PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia 2012 ·Value in Health ·(unknown), Christopher R. Flowers, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Thomas J. Kipps, Susan Lerner, Neil E. Kay, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S. Swern, (unknown), (unknown), Kathleen A. Sullivan, Gale Harding, Michael J. Keating	1
7	Recent advances in the biology and management of acute lymphoblastic leukemia in adults 2007 ·Cancer treatment and research ·Owen A. O’Connor, Mark A. Weiss	0
8	Purine Analogue-Based Chemotherapy Regimens for Second-Line Therapy in Patients With Chronic Lymphocytic Leukemia 2006 ·Seminars in Hematology ·Nicole Lamanna, Mark A. Weiss	2
9	Inflammatory Myofibroblastic Tumors of the Kidney: A Clinicopathologic and Immunohistochemical Study of 12 Cases 2003 ·The American Journal of Surgical Pathology ·Linda Kapusta, Mark A. Weiss, Jennifer Ramsay, Antonio López-Beltrán, John R. Srigley	69
10	Multicenter clinical trial results with the LifeSite® hemodialysis access system 2002 ·Kidney International ·Steve J. Schwab, Mark A. Weiss, (unknown), (unknown), Jerry W. Jackson, Toros Kapoian, (unknown), Melvin Rosenblatt, (unknown), (unknown), Jack Work, (unknown), Brian F. Stainken, (unknown), John A. Moran	48
11	A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia 2002 ·Cancer ·Mark A. Weiss, Timothy Aliff, Martin S. Tallman, Stanley R. Frankel, Matt Kalaycio, P. Maslak, Joseph G. Jurcic, David A. Scheinberg, (unknown)	23
12	Induction Therapy of Adult Acute Lymphocytic Leukemia without the Use of Vincristine or Prednisone 2001 ·Hematology/Oncology Clinics of North America ·Mark A. Weiss	4
13	Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy 2001 ·Leukemia ·Karen Seiter, (unknown), (unknown), (unknown), James Weisberger, (unknown), (unknown), Mark A. Weiss, R Kancherla, Tauseef Ahmed	25
14	Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria 2001 ·British Journal of Haematology ·David J. Araten, David Swirsky, Anastasios Karadimitris, Rosario Notaro, Khédoudja Nafa, Monica Bessler, Howard T. Thaler, Hugo Castro‐Malaspina, Barrett H. Childs, Farid Boulad, Mark A. Weiss, Nikolaos Anagnostopoulos, Abdullah Kutlar, David G. Savage, Richard T. Maziarz, Suresh C. Jhanwar, Lucio Luzzatto	34
15	A symposium on controversies in the pathology of transitional cell carcinomas of the urinary bladder, Part II. 1996 ·PubMed ·Mahul B. Amin, William M. Murphy, Victor E. Reuter, Jae Y. Ro, (unknown), Mark A. Weiss, John N. Eble, R H Young	11
16	A comparison of clinical, pathological and radiological findings with magnetic resonance imaging studies of lymphomas in patients with Sj�gren's syndrome 1994 ·European Archives of Oto-Rhino-Laryngology ·G. Grevers, Stephan Ihrler, Th. Vogl, Mark A. Weiss	19
17	The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia breakdown → 1992 ·Annals of Internal Medicine ·Stanley R. Frankel, A Eardley, Gregory Y. Lauwers, Mark A. Weiss, Raymond P. Warrell	513
18	High Linoleic Acid Diets Ameliorate Diabetic Nephropathy in Rats 1990 ·American Journal of Kidney Diseases ·Uno Barcelli, Mark A. Weiss, (unknown), (unknown), Brian K. Thompson	36
19	A thromboxane synthetase antagonist ameliorates progressive renal disease of Dahl-S rats 1988 ·Kidney International ·(unknown), Yasushi Ito, Mark A. Weiss, B S Ooi, Victor E. Pollak	23
20	Alport’s Syndrome: Risk of Glomerulonephritis Induced by Anti-Glomerular-Basement-Membrane Antibody after Renal Transplantation 1988 ·The Nephron journals/Nephron journals ·Bharat Shah, (unknown), (unknown), David H. Clyne, Wesley J. Alexander, Mark A. Weiss	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact